ArticleArab journal of urology2026
On-demand silodosin 4 mg vs dapoxetine 60 mg in treatment of primary premature ejaculation: A prospective randomized study.
Article in Arab journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the efficacy and tolerability of Silodosin 4 mg and Dapoxetine 60 mg in the treatment of primary premature ejaculation. Methods: This is a prospective study that was carried out on 95 adult sexually active patients with PE (IELT < 1 min) attending outpatient clinic, Urology Department, Benha University Hospitals. Patients with primary PE were randomly assigned to two groups; group A: 48 patients who took silodosin 4 mg 2 h before intercourse (on demand) at least 6 times intercourse/month for 2 months and group B: 47 patients who took dapoxetine 60 mg the same like silodosin. Throughout the research, eight patients in silodosin group and seven patients in dapoxetine group were lost to follow-up and subsequently excluded from the study. Results: The average age of primary PE patients included in the study was 33.4 ± 2.9. IELT significantly increased from 21.4 ± 13.8 to 275 ± 63.4 s in group A and significantly increased from 24.9 ± 14.3 to 293.5 ± 54.3 s in group B. Also both studied groups showed significant improvements in premature ejaculatory profile (PEP), the premature ejaculation diagnostic tool (PEDT), and the Arabic index of premature ejaculation (AIPE) with fewer side effects in group A. Conclusion: Both Silodosin 4 mg and Dapoxetine 60 mg significantly improved IELT and sexual function scores in primary PE patients. However, Silodosin exhibited a more favorable tolerability profile with fewer side effects, making it a safer, clinically effective alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.